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Background: There is an urgent need to rapidly distinguish COVID-19 from other respiratory conditions,
including influenza, at first-presentation. Point-of-care tests not requiring laboratory- support will speed
diagnosis and protect health-care staff. We studied the feasibility of using breath-analysis to distinguish
these conditions with near-patient gas chromatography-ion mobility spectrometry (GC-IMS).
Methods: Independent observational prevalence studies at Edinburgh, UK, and Dortmund, Germany,
recruited adult patients with possible COVID-19 at hospital presentation. Participants gave a single breath-
sample for VOC analysis by GC-IMS. COVID-19 infection was identified by transcription polymerase chain
reaction (RT- qPCR) of oral/nasal swabs together with clinical-review. Following correction for environmen-
tal contaminants, potential COVID-19 breath-biomarkers were identified by multi-variate analysis and com-
parison to GC-IMS databases. A COVID-19 breath-score based on the relative abundance of a panel of volatile
organic compounds was proposed and tested against the cohort data.
Findings: Ninety-eight patients were recruited, of whom 21/33 (63.6%) and 10/65 (15.4%) had COVID-19 in
Edinburgh and Dortmund, respectively. Other diagnoses included asthma, COPD, bacterial pneumonia, and
cardiac conditions. Multivariate analysis identified aldehydes (ethanal, octanal), ketones (acetone, butanone),
and methanol that discriminated COVID-19 from other conditions. An unidentified-feature with significant
predictive power for severity/death was isolated in Edinburgh, while heptanal was identified in Dortmund.
Differentiation of patients with definite diagnosis (25 and 65) of COVID-19 from non-COVID-19 was possible
with 80% and 81.5% accuracy in Edinburgh and Dortmund respectively (sensitivity/specificity 82.4%/75%;
area-under-the-receiver- operator-characteristic [AUROC] 0.87 95% CI 0.67 to 1) and Dortmund (sensitivity /
specificity 90%/80%; AUROC 0.91 95% CI 0.87 to 1).
Interpretation: These two studies independently indicate that patients with COVID-19 can be rapidly distin-
guished from patients with other conditions at first healthcare contact. The identity of the marker com-
pounds is consistent with COVID-19 derangement of breath-biochemistry by ketosis, gastrointestinal effects,
and inflammatory processes. Development and validation of this approach may allow rapid diagnosis of
COVID-19 in the coming endemic flu seasons.Keywords:
Covid-19 diagnostics
Breath-analysis
Breath-testing
Gas chromatography-
ion mobility spectrometry
GC-IMS
Multi-variate analysis
Aldehydes
Ketones
Methanolas).
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Evidence before this study
Previous porcine and human studies have identified breath bio-
chemistry derangements in acute respiratory distress syn-
drome that resulted in elevated exhaled ethanal signals. In-
vitro studies have differentiated between viral (influenza A)
and bacterial (Streptococcus pyogenes) infections based on
breath aldehydes. Methanol and ketones have also been pro-
posed as markers for gastrointestinal inflammation, and keto-
sis, respectively.
Added value of this study
A change in breath-biochemistry has been observed in two
independent pilot-studies that is consistent with a host-
response that may be attributed to a combination of ketosis,
impaired gastrointestinal function and inflammatory responses.
The practicality of undertaking point-of-care breath-sampling
and breath-testing has been demonstrated, and the area-
under-the-receiver operator characteristic (AUROC) for differ-
entiating COVID-19 positive from COVID-19 negative patients
ranged between 0.87 and 0.91. A panel of volatile organic com-
pounds (ethanal, octanal, acetone, butanone, methanol, hepta-
nal and a feature yet to be identified) is hypothesised to
provide the basis of a COVID-19 rule- in/rule-out breath-test.
Implications of all the available evidence
The development of COVID-19 following infection by SARS-
CoV-2 appears to be accompanied by significant changes in the
exhaled concentrations of a panel of volatile organic com-
pounds consistent with whole system disturbance. A higher-
powered study with time series data may establish how a vola-
tile organic compounds (VOCs) profile develops with infection,
incubation and disease-progression, enabling the development
of a COVID-19 breath-test.1. Introduction
The strategic importance of effective testing for SARS-CoV-2 infec-
tion has been emphasised from the outset of the COVID-19 pan-
demic; most notably by the WHO Director General with the
statement “We have a simple message to all countries - test, test,
test”. Until deployment of an effective vaccine, testing will be the
basis for successful coordination of clinical and public health
responses to outbreaks [1]. This will be particularly important for the
management of COVID-19 alongside a winter influenza epidemic.
COVID-19 testing is currently based on quantitative reverse tran-
scription polymerase chain reaction (RT-qPCR) assays detecting
SARS-CoV-2 RNA in nasopharyngeal (NP) and/or oral swabs. These
tests: require authorised laboratories with a minimum Biological
Safety Class 2 specification; take time to ship, process and report;
and are prone to false negative results (from errors in swab sampling
or laboratory processing, or because the virus is not yet/no longer
present in the oropharynx) [2]. The false negative rates for “one-
time” NP testing by RT-qPCR is 30% to 50% for COVID-19 samplesz et al., Diagnosis of COVID
edicine (2020), https://doi.oracquired in community or clinical- care settings [3], while the area-
under-the-receiver operator characteristic (AUROC) for a single RT-
qPCR test is about 0.8 [4,5,6]. Repeat RT-qPCR tests, combined with
haematological variables and chest computed tomography are
advised for diagnosis, along with caution in the interpretation of neg-
ative RT-qPCR tests [7].
A point-of-care test that: enabled rapid differentiation of
COVID-19 from other viral and/or bacterial pneumonia, and other
respiratory and cardiac conditions; provided prognostic insights
into the staging of COVID-19; and monitored treatment efficacy
would markedly enhance the capability of healthcare services to
respond.
Analysis of exhaled volatile organic compounds in the breath
using gas chromatography with either mass spectrometry (GCMS)
or ion mobility spectrometry (GC-IMS) has been proposed for diagno-
sis of COVID-198 and pneumonia [9]. Studies of patients with acute
respiratory distress syndrome (ARDS) [10,11] and influenza in pigs
[12] have identified candidate markers for detection. Breath-analysis
is attractive because it offers: point-of- care location; rapid results (<
10 min) without dependency on reagents; non-invasive sampling
with a low biosecurity burden; and usability in a world-wide range
of scenarios, including low-resourced environments such as commu-
nity or primary care settings.
Because COVID-19 is a multi-system condition [13,14], we
hypothesised that a combination of inflammatory and host-responses
VOCs would differentiate between the breath of patients with COVID-
19 and those with other respiratory or cardiac problems. At the
beginning of the epidemic, independent feasibility studies were rap-
idly set in Germany and United Kingdom with the objectives: to trial
point-of-care testing using self-contained GC-IMS breath-analysers
in two hospitals; and evaluate the breath biochemistry for possible
markers of COVID-19.
2. Methods
2.1. Ethics
Two independent studies were set up in two hospitals: Royal
Infirmary of Edinburgh (RIE, Ethics approved by Institutional Review
Board (ref RIE, 20/SS/0042), UK, and in Klinikum Dortmund (KD,
Ethics approved by Institutional Review Board ref IfADo 176/2020),
Germany.
Patients were assessed by the treating clinician to establish if they
were competent and had the capacity to consent to participate. This
assessment was documented in their medical notes (‘this patient is
eligible and capable of providing written informed consent’). Patients
lacking capacity who were unable to provide consent were not
approached to take part in this study
Note that there was always a researcher and witness present dur-
ing the consent process where the study was explained and the
patient given a Patient Information Sheet that explained the aims of
the study, the potential risks, and benefits of the study procedures.
Additionally, the patients were given an Informed Consent Form, and
time to consider the trial and ask questions regarding their participa-
tion. Once the information sheet and informed consent form had
been studied the patient was asked to confirm to the researcher and
witness that they understand all the information, and what they are
consenting to. Patients who agreed to participate in the study-19 by analysis of breath with gas chromatography-ion mobility
g/10.1016/j.eclinm.2020.100609
Table 1
Participants’ information.
Dortmund (n = 65) Edinburgh (n = 33)
COVID-19 ve COVID19 +ve COVID19 ve COVID-19 +ve
No of participants 55 10 12 21
RT-qPCR SARS-COV-2 * 55 10 8 17
Other diagnoses 
Asthma / COPD 2 4
Bacterial pneumonia 3 1
Viral pneumonia 1
Others: viral infections, respiratory tract infections,
cardiac, and not diagnosed
50** 6
Characteristics
Age (median / IQRy; years) 43 / 27 39 / 18 59.5 / 3 61 / 19
Sex (F / M; n) 20 / 35 5 / 5 10 / 2 7 / 14
Smoking status
Smoker (n) 13 0 1 0
Former smoker (n) 9 2 6 8
Never smoked (n) 12 8 5 12
Unknown status ** (n) 21 0 0 1
Obesity - BMI>30 (n) 7(21 unknown**) 4 3 5
Heart failure history (n) 5 (21 unknown**) 2 1 0
COPD (n) 7 (21 unknown**) 2 2 2
Duration of symptoms at presentation (median, IQRy ; days) 3 / 5 5 / 3 7/11 9 / 7
Outcomes
Duration in hospital (median / IQRy ; days) 7/11 9/19 0.5 /3 5 / 3
Hospitalised (n) 13 8 6 19
Admitted to intensive care (n) 5 2 0 4
Intubated/ventilated (n) 1 1 0 0
Deaths (n) 0 0 0 3***
* COVID-19 status was determined on adjudication and PCR and clinical features, patients included in modelling of the data.
** 21 Dortmund patients were discharged home without obtaining a formal non-COVID-19 diagnosis and limited meta data was obtained.
*** The three patients who died in Edinburgh were not admitted to ICU due to co-morbidities and poor prognosis.
y Interquartile range (IQR) was calculated as difference between upper (Q3) and lower (Q1) quartiles.
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the study consent form.
It is important to note that due to the nature SARS-COV-2 it was
not feasible to retain a paper copy of a consent form signed by the
participant once they had handled it. This is why the consent form
was signed by a witness (e.g. a relative or another staff member).
2.2. Participants
The participant numbers presented in this paper arise from the
(feasibility) first phase of the study that was conducted during the
initial patient surges at both centres. The decisions to present
these findings now were based on: marked falls in COVID-19 prev-
alence in Dortmund and Edinburgh; instrument availability fol-
lowing sustained environmental contamination that required
instrument maintenance at Edinburgh. No formal power calcula-
tion was available at the outset of each study for the signals, and
effect sizes had yet to be determined. Post-hoc evaluation indicates
that the collected sample sizes, were sufficient to support the pre-
liminary analysis.
Edinburgh participants were recruited between March 31 and
April 22, 2020, from patients presenting to the emergency depart-
ment exhibiting respiratory symptoms who were considered to have
possible COVID-19. Participants were excluded if they were not
breathing spontaneously and/or receiving respiratory support. Each
patient was swabbed on presentation for RT-qPCR testing and admit-
ted if clinically indicated. Patient clinical data were collected using
the Research Electronic Data Capture web application [15], see
Table 1. The RT-qPCR test was discarded if patient opt-out from the
study, according to the study protocol.
Dortmund participants were similarly recruited between April 11
and June 18, 2020, from patients presenting to the emergency
department or outpatient clinic exhibiting respiratory symptoms.
Each participant was swabbed on presentation or within 24 h ofPlease cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.oradmission for RT-qPCR testing. Patient clinical data were collected
using a questionnaire and recorded in Excel, Table 1.
A COVID-19 diagnosis was made by senior physicians (MJR and KB
in Edinburgh and by FH, RE, OM, MT and SY in Dortmund) based on
clinical presentation, q- PCR test results and radiological findings.
2.3. GC-IMS sample collection and processing
Measures to supress the risk of SARS-COV-2 contamination of the
instruments included the use of sterile, single use sampling devices,
figure S2; fitting a high efficiency particulate air (HEPA) filter to the
gas outlet of the instrument); maintaining 60 ⁰C at all times to the
analyte pathways in the instrument; and daily 100 °C instrument
clean-out methods, run for a period of minimum 8 h. There was no
direct contact between participants and the instruments and the
external casing of the instrument was wiped down after each sample
analysis,
A self-contained GC-IMS instrument configured for manual sam-
ple injection (BreathSpec,G.A.S. Dortmund; figure S 1) was set up in
two hospital. The instruments were the same model and configura-
tion and consisted of a heated six-port sample inlet-valve, con-
nected to a 3 m, 0.53 mm inner-diameter capillary gas
chromatography column, with a 0.5 mm thick crossbond carbowax
polyethylene glycol WAX stationary phase (MXT-WAX), interfaced
to a linear IMS. A recirculating gas flow unit (CGFU) supplied puri-
fied-air to the GC and IMS circuits. The IMS was fitted with a
5.68 keV, 370 MBq 3H beta ionisation source, and data were trans-
ferred with a USB memory-stick and uploaded to a data repository.
The studies were set independently, without a knowledge of each
other in the first phase of the research, which is why slightly differ-
ent instrument methods (operational parameters) were used
between the sites (table S 1).
Participants at both sites provided a single breath-sample by
exhaling through a single-use disposable polypropylene Haldane-19 by analysis of breath with gas chromatography-ion mobility
g/10.1016/j.eclinm.2020.100609
Fig. 1. Workflow showing data processing and modelling steps used to create multivariate classification models that discriminated for COVID-19. VOC’s Markers (Mn, where n = 1 to
12) used in the final PCA modelling and Ratiometric scoring were derived from integrating the discovery studies and are highlighted by Dashed-dotted lines (RIE) and Dashed lines
(KD).
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through the side-wall to take a single-use disposable polypropylene
5 cm3 syringe. The tube was either fitted with two one-way mouth-
pieces at each end of the Haldane tube (Edinburgh), or only one at
the inlet (Dortmund) and is shown in figure S 2. Participants were
asked to breath out slowly through the tube. The procedure is not
considered an aerosol-generating procedure (AGP) [16]. On comple-
tion of exhalation, a 5 cm3 sample of their end-tidal breath was with-
drawn into the syringe, the syringe immediately removed from the
sampler, connected into the GC-IMS inlet, and 1 cm3 automatically
injected on to the GC column for analysis.Please cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.orQuality control (QC) covered 15 spectral and operational parame-
ters assessed from a daily environmental sample collected every
morning (RIE) or for every breath-sample (KD; Table S 2). The breath-
acetone signal was also assessed to confirm that sampling occurred
correctly - a weak or missing acetone signal indicating a fault in sam-
ple collection and/or analysis, resulting in data being excluded.
2.4. Data modelling
The workflow for data processing and statistical analysis is shown
in Fig. 1. Edinburgh data were extracted into a .csv format file using-19 by analysis of breath with gas chromatography-ion mobility
g/10.1016/j.eclinm.2020.100609
Fig. 2. An example of 3D GC-IMS surface plots of breath data acquired by the two hospital sites (RIE - Edinburgh top and KD - Dortmund bottom). Note: tr  retention time in sec, tDr
 relative drift time and I  intensity in V. Markers distinguishing between COVID-19 positive and negative patients, used in the final PCA Modelling Mn (where n is the marker
number) are highlighted in the square boxes.
Table 2
VOC biomarkers selected as best discriminants between COVID-19 positive and negative patients, in both stud-
ies during discovery and final modelling phases, together with compounds analytical characteristics. Note: RIE -
Edinburgh, KD  Dortmund.
Discovery Classification {tr/s tDr
RIE KD RIE KD RIE KD RIE KD
M1 Ethanal " " @ @ 164 91 1.022 1.027
M2 Acetone " " @ @ 186 99 1.159 1.157
M3 Acetone/2-Butanone cluster "  @ £ 2 09 109 1.228 1.228
M4 2-Butanone  " @ @ 209 109 1.300 1.277
M5 Methanol Monomer # # @ @ 207 108 0.99 0.985
Methanol Dimer 1.036 1.071
M6 Octanal " " @ £ 5 90 365 1.45 1.44
M7 Feature 144 "  @ £ 5 83 ND 1.078 ND
M8 Isoprene  " £ £ 158 88 1.092 1.081
M9 Heptanal  " £ @ 430 237 1.362 1.365
M10* Propanol  " £ £ ND 153 ND 1.293
M11* Propanal  " £ £ 177 95 1.058 1.092
Note: tr: retention time (s); t: relative drift time; ND  not detected.
* : excluded from all data models; "/#: increased/decreased exhaled concentration in COVID-19 positive par-
ticipants; @/ £: included/not included in classification model.
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malised relative drift time, to compensate for between-run instru-
ment variation [17,18]. The data were then processed using MATLAB
to generate integrated signal volumes for every isolated-feature and
these were placed into a 2- dimensional matrix for further data-
modelling. An average of 80 features were extracted from each
breath-sample.
Dortmund data were analysed with G.A.S. VOCCal software (Gas
Dortmund) with retention times and drift time normalisation to com-
pensate for the inter- run instrument variation. Signal peaks were
integrated manually. Some features, such as methanol, were
obscured by the reactant ion peak signal; this complication was
resolved by subtraction of the reactant ion peak signal. Approxi-
mately, 80 features were extracted. from each breath-analysis. A
comparison of example breath-data obtained from the two centres is
shown in Fig. 2.Please cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.orThe drift-time aligned breath-data from the 33 Edinburgh partici-
pants were placed into a data-matrix and candidate COVID-19
breath-markers identified from a three-step multi- variate analysis
data work-flow, based on the use of the SIMCA-P+ software with inte-
grated 7-fold cross validation groups to protect against overfitting
(Version 16.1, Umetrics, UK). The work-flow comprised of: data-scal-
ing, removal of non-discriminatory features, and isolation of discrimi-
natory features. The log(10) data were Pareto-scaled before
orthogonal partial least square discriminant analysis (OPLS-DA) was
applied to identify and exclude non-discriminatory features from fur-
ther analysis, identifying six exhaled VOC’s candidate markers
(Table 2). At this stage data from 8 patients were excluded from fur-
ther analysis due to either: a) no q-PCR tests results (n = 5) were
available or there was no agreement between q-PCR test results and
medical diagnosis (n = 3).
Breath-data from 65 Dortmund participants were visually identi-
fied and placed into a peak gallery where they were statistically-19 by analysis of breath with gas chromatography-ion mobility
g/10.1016/j.eclinm.2020.100609
Fig. 3. PCA-X (top-left) and dendrogram (bottom) plots of Edinburgh COVID-19 query data. Showing the data similarities between the participants with COVID-19 and other diag-
noses. AUROC (top-right) was 0.81. Note five cases were misclassified see Discussion.
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tom). These data were Pareto-scaled and bespoke multivariate analy-
sis software for GC-IMS used to undertake Principal Component
Analysis (PCA, G.A.S. Dynamic PCA software). Nine VOCs were identi-
fied as potentially discriminating for COVID- 19 (Table 2),
The findings from the two independent studies were shared and
an adjudicated VOC panel selected for running a PCA stratification
model (Table 2, Figs. 13) with participants with definite diagnosis,
for whom q-PCR and the adjudicated diagnosis agreed (90 partici-
pants: 25 RIE and 65 KD). Finally, the data obtained from PCA models,
was assessed with hierarchical clustering analysis which categorizes
similar samples in the same categories. The results are presented in
the form of the dendrogram, based on Ward's minimum variance
method, sorted by score size.
The compounds identified by PCA multi-variate analysis indicated
that changes in breath- biochemistry followed the same pattern in
both studies with elevated ketone and aldehyde signals accompanied
by a suppressed methanol signal, and an unidentified feature 144
also noted as potentially significant. To facilitate data sharing and
interpretation between the studies the data from these compounds
were combined to produce a COVID-19 breath- score (C19) defined as:
C19 ¼
IAldehydes þ IKetones þ IFeature 144
Imethanol
ð1Þ
Where IAldehydes is the sum of the log peak volume of the VOCs
ethanal and octanal, IKetones is the sum of the log peak volume forPlease cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.oracetone and 2-butanone, and IFeature 144 is the log peak volume of the
unidentified Feature 144. similarly, for Imethanol. The classifier for the
detection of COVID-19 from the C19 score was defined as the upper
95% confidence interval for C19 of the non-COVID-19 breath-tests. A
C19 value above this boundary was classified as COVID-19 positive.2.4.1. Role of the funding source
The funders of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. The
corresponding authors had full access to all the data in the study and
had final responsibility for the decision to submit for publication.3. Results
Ninety-eight patients were recruited, of whom 21/33 (63.6%) and
10/65 (15.4%) were adjudicated to have COVID-19 in Edinburgh and
Dortmund, respectively (Table 1). The diagnoses of non-COVID-19
patients included exacerbation of asthma and COPD (RIE 9.1%, KD
3.1%), bacterial pneumonia (RIE 3.0%, KD 4.6%), and others including
cardiac conditions (RIE 24.3%, KD 18.5%). 69.1% of those testing nega-
tive at Dortmund were returned to primary care and did not receive
a formal hospital diagnosis.
Six VOC in the Edinburgh GC-IMS data: ethanal, octanal, acetone,
acetone/butanone mixed cluster, and methanol (level 2 identification
[19] against 2014 NIST-RI data base and-19 by analysis of breath with gas chromatography-ion mobility
g/10.1016/j.eclinm.2020.100609
Fig. 4. PCA-X (top-left) and dendrogram (bottom) plots of Dortmund COVID-19 query data. AUROC (top-right) was 0.91.
ARTICLE IN PRESS
JID: ECLINM [m5G;October 24, 2020;10:33]
D.M. Ruszkiewicz et al. / EClinicalMedicine 00 (2020) 100609 7G.A.S. Drift Time Library) discriminated between patients with
COVID-19 and those other diagnoses (Table 2, Fig. 3). An additional,
as yet unidentified, VOC (Feature 144) was also noted at a retention
time of 583 s and relative drift time of 1.078. Feature 144 was associ-
ated with more severe disease (figure S 4). Exhaled methanol concen-
trations were lower in COVID-19 participants; the other five
compounds were elevated in participants with COVID-19.
In addition to the six Edinburgh VOCs, isoprene, propanal, hepta-
nal, and propanol were identified in Dortmund (Table 2). The precise
features identified at the two sites were different due to modest dif-
ferences in instrument set up and operating conditions, including
background contamination levels. For example, the Edinburgh study
identified a mixed acetone and butanone proton-bound mixed ion
cluster, while Dortmund identified a butanone ion (Table 2). These
differences in set up also meant that the Dortmund instrument could
not record Feature 144 because the elution time of this component in
the Dortmund instrument was longer than the data acquisition time.
Hierarchical analysis of the Edinburgh data (Fig. 3), based on the
agreed q- PCR/adjudicated diagnosis, identified three classes of par-
ticipant from the PCA model. The first class, termed ‘negative’, con-
tained nine participants. Six were COVID-19 negative (6 of 8 [75%] of
total negative cases with a mixture of: viral or bacterial pneumonia,
asthma, or heart failure) and three were positive (3 of 17 [17.6%] total
positive cases). A second ‘positive’ class contained ten COVID-19 posi-
tive participants (10 of 17 [58.8%]) and 1 COVID-19 negative partici-
pant (1 of 8 [12.5%] with a diagnosis of exacerbation of asthma). A
third (positive) class contained four COVID-19 positive (24%) cases;
on the basis of hierarchical clustering, this class was termedPlease cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.or‘borderline-positive’. The resultant PCA stratification model had an
82.4% sensitivity and 75% specificity with an AUROC of 0.87 (95%CI
0.61 to 1) for distinguishing COVID-19 patients from other patients.
The data were also modelled for ruling out COVID-19 with the same
result and AUROC.
The Edinburgh PCA stratification model was compared against a
clinical assessment of the ultimate severity of the participants’ dis-
ease during hospital admission, with COVID-19 patients assessed as
having fatal, severe/intubated/ITU care, and mild disease. The ‘posi-
tive’ class containing ten COVID-19 cases contained all three fatali-
ties, 3 of 4 severe/intubated/ITU care cases, and 4 of 10 mild cases.
The ‘borderline-positive’ cases were all mild; the single false negative
case was also scored as mild. This suggests that the PCA may be able
to identify - at first presentation to hospital - COVID-19 patients who
will go on to develop more severe disease.
Dortmund data were similarly modelled with PCA (Fig. 4); hierar-
chical analysis resulted in a more complicated pattern of five nega-
tive, positive, or borderline positive classes. Of the two negative
classes, the largest had 41 participants q-PCR/adjudicated as COVID-
19 negative cases (41 of 55 [74.5%] total negative cases) and one par-
ticipant q-PCR/ adjudicated as COVID-19 positive (1 of 10 [10.0%]
total positive cases). A second distinct, smaller negative class
included only three COVID-19 negative cases (3 of 55 [5.5%], all of
whom were hospitalised (viral infection with rash, urinary tract
infection, gastroenteritis). There were two positive classes with the
first including six COVID-19 positive cases (6 of 10 [60.0%] total posi-
tive cases) and the second including two COVID-19 positive cases (2
of 10 [20.0%] total positive cases). The borderline positive class-19 by analysis of breath with gas chromatography-ion mobility
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COVID-19 (20% of total negative cases). Three of these negative cases
were tested >7 days after the onset of influenza type symptoms; one
was hospitalised while the other two recovered in the community.
The remaining eight were tested within 3 days of onset of influenza
type symptoms and were discharged home.
The Dortmund PCA stratification model had an 90% sensitivity and
80% specificity and an AUROC of 0.91 (95%CI 0.87 to 1) for distin-
guishing COVID-19 patients from other patients. Modelling to rule
out COVID-19 had a sensitivity of 98.2% and specificity of 70%
(AUROC = 0.91). The two severe COVID-19 cases were accurately
identified by the PCA. Four severe cases were classified correctly as
COVID-19 negative, with diagnosis of: community acquired pneumo-
nia with COPD, cryptogenic organizing pneumonia, aortic valve ste-
nosis and COPD. The COVID-19 case placed in the borderline positive
class had a diagnosis of community acquired pneumonia and non-ST-
segment elevation myocardial infarction.
The Edinburgh C19 breath-score for COVID-19 cases was 1.13-fold
that of the mean for the COVID-19 negative participants, with a t-sta-
tistic of 1.98, and 23 degrees of freedom. The critical value for a one-
tailed t-test was 1.72. The Dortmund C score yielded a 1.24-fold
COVID-19 case enhancement with a t-statistic of 2.53, 63 degrees of
freedom, and a one- tailed critical t-value of 1.67 (figure S 5).
4. Discussion
It will be extremely important over the coming months and years
to be able to distinguish COVID-19 from other respiratory and cardiac
conditions, particularly influenzae infection, on first presentation to
healthcare services, whether hospital or primary care. Analysis of
VOCs in breath using GC-IMS, or appropriate sensors, offers the possi-
bility of rapid near- patient diagnosis if a characteristic signature can
be identified. The preliminary data presented here, in two indepen-
dently set-up feasibility studies, suggests a distinct COVID- 19
breath-biochemistry derangement that may be able to diagnose or
exclude COVID-19.
The C19 score differentiates quite well between participants with
COVID-19 and those with other respiratory diseases. Larger studies
are needed to refine and quantify the accuracy of this GC-IMS
approach in diagnosing and excluding COVID-19.
It is important to note how Edinburgh’s and Dortmund’s instru-
mental methods, data processing and preliminary modelling were
independent and un-targeted. Molecular identities were not known
during data processing and modelling, and no a priori assumptions or
parameters used to isolate the VOCs reported in this work. The resul-
tant duplication of the findings serves to strengthen the resultant
hypothesised COVID-19 breath biomarker panel and to reduce the
likelihood of these results arising from false discovery.
At this stage exclusion criteria have not been applied to the data
to provide balance on gender and age distribution within the two
sites. This may be a source of bias with potentially confounding hid-
den factors; however, the two study groups are complementary with
respect to age and the overall gender distribution is 42% female to
58% male. The identification of similar discriminator chemistry across
the two different groups is an additional observation on the attrib-
utes of two independent sites with different cohorts with indepen-
dent testing and data processing methods arriving at a single
conclusion.
We found preliminary data of a relationship between breath-bio-
markers on presentation  in self-ventilating patients - and COVID-
19 severity over their hospital stay. However, the sample-times in
this study were not coordinated against onset of symptoms, since
participants were recruited on their presentation on hospital, mean-
ing that samples were obtained from participants at different stagesPlease cite this article as: D.M. Ruszkiewicz et al., Diagnosis of COVID
spectrometry - a feasibility study, EClinicalMedicine (2020), https://doi.orof COVID-19. Experiments with time series sampling, involving a
larger COVID-19 cohort, will be required to determine whether
breath- analysis is able to reliably predict severity and progressive
COVID-19.
The identity of the marker compounds identified in this study are
consistent with a combination of extrapulmonary metabolic, and gas-
trointestinal manifestations of COVID- 19 within the body as well as
airway inflammatory responses [14]. “Direct binding of SARS- CoV-2
to ACE2 on b-cells” in the pancreas has been proposed as a contribut-
ing pathology to insulin deficiency and hyperglycaemia with COVID-
19 patients. 64% of cases exhibiting ketosis have no underlying diabe-
tes, and ketosis has been noted as indicative of a more serious pro-
gression of COVID-19 with increased hospitalisation times and
mortality [20]. Exhaled methanol is attributed to gut microbiota act-
ing on fruit and vegeTables (pectin), as well as the breakdown of
aspartame and carboxyl-methylesters [21]. Decreased levels of uri-
nary methanol have been observed with inflammatory gastrointesti-
nal conditions (e.g. ulcerative colitis and Crohn’s disease) [22]. As
well as multi-factor intestinal tissue damage (inflammation, vascular
damage and direct tissue damage from the virus), the possibility of
SARS-CoV-2 interactions with gut microbiota leading to reduced
activity with accompanying reductions in methanol production also
exists [14]. Aldehydes are derived, along with hydrocarbons, from
lipid peroxidation and inflammatory processes and have been
reported widely in a range of respiratory conditions [23].
This work builds on other studies of VOC and GCMS or GC-IMS
analysis in respiratory disease in that it has identified a panel of VOC
biomarkers consistent with the multi-system presentation of COVID-
19 that is supported by previous research. ARDS detection by breath-
analysis with GCMS reported markers linked to lipid-peroxidation
(octane, ethanal and 3- methylheptane) with an AUROC of 0.8.10,11
Influenza A detection in pigs using breath- analysis has also been
described, and progression was monitored through the analysis of six
breath VOC (ethanal, propanal, n-propyl acetate, methyl methacry-
late, styrene and 1,1- dipropoxypropane).12 Further an in-vitro study
of human epithelial-like Detroit cells inoculated with influenza A and
Streptococcus pyogenes identified significant differences in VOC con-
centrations between non-infected and infected cells with S pyogenes,
associated with increased emissions of ethanal, propanal and N-pro-
pyl acetate linked to viral Influenza [24].
Recently a two-dimensional gas chromatography with photoio-
nisation detection study applied multi variate analysis to identify a
panel of nine VOC that discriminated ARDS with an accuracy of
82.4% (although AUROC and identities of the nine compounds
were not reported) [25]. Furthermore, a clinical GC-IMS study has
reported discrimination of COVID-19 from influenza A, although
the application of canonical discriminant analysis (a supervised
technique) to influenza and COVID-19 breath-samples collected in
separate batches means the reported AUROC of 1 is difficult to
assess due to the possibility of hidden batch effects confounding
the data analysis [8]. Nevertheless, both of these studies emphasise
and support the proposition and feasibility of breath-testing for
COVID-19.
GC-IMS was selected for these studies as the instrument and
methods have been developed for use in emergency departments,
with low operational overheads and a low NASA task load index [26].
The rapid and simple sampling technique does not generate viral
exposure risk for clinicians and does not require additional bio-secu-
rity safeguards, as it does not involve positive pressure and is not
considered an aerosol generating procedure. However, GC-IMS is vul-
nerable to background contamination; care is therefore needed in
selecting where to site the instruments and how to operate them to
mitigate this issue. Disinfection and cleaning routines require careful
management.-19 by analysis of breath with gas chromatography-ion mobility
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duce confounding data and false discovery if not carefully managed.
In these studies, dietary factors were dispersed and randomised
across both study sites and across each day. Individuals’ dietary sig-
natures were processed out during the statistical modelling stage
and the absence of a systematic sampling schedule prevented the
introduction of a dietary artefact through inadvertent synchronisa-
tion with meal times.
One limitation of GC-IMS, compared to GCMS, is an inability to
resolve signals that coelute, because of charge transfer phenomena
that occur in the instrument’s ionisation source [27]. Co-eluting com-
pounds produce a mixed signal that cannot be deconstructed. With
the slightly different chromatographic methods and environmental
contamination between the two studies, co-elution artefacts were
not necessarily aligned and so it is not surprising that they produced
similar but not identical results. The differences in methods also pre-
cluded the Dortmund study from isolating Feature 144. Further
development of this work will require aligned techniques which
remove such disparities. In addition, to enable GC-IMS to analyse
straight chain and methylated hydrocarbons in the inflammatory
marker panel [10,11], an ionisation source needs to be developed to
include photo-ionisation mechanisms as well as the atmospheric
pressure ionisation charge transfer reactions used in this work.
Feature 144 was markedly elevated in the most serious cases
(figure S 4) suggesting it might be useful as a marker of severity.
GCMS studies are required to identify it because it was not found in
current IMS databases [28]. Its identification may provide useful
information for understanding the unusual severity of COVID-19
compared to other viral pneumonias [14].
In conclusion, we report here that near-patient GC-IMS analysis
detects changes in breath- signatures of COVID-19 patients that may
be able to differentiate them from non-COVID-19 respiratory and car-
diac conditions and that are consistent with the disease’s multi-sys-
tem manifestations. Larger studies are required to test this
hypothesis, together with complementary GCMS studies. If shown
to be reliable, it offers the possibility for rapid identification or exclu-
sion of COVID-19 in emergency departments or primary care that
will improve management of patients and safety of healthcare staff.Declaration of Competing Interest
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